Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
11 sept. 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy...
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
23 août 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
08 août 2017 16h14 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2017. Total revenue was $20.4...
Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
26 juil. 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., July 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second...
Inovio Announces Pricing of Public Offering of Common Stock
19 juil. 2017 22h09 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common...
Inovio Announces Proposed Public Offering of Common Stock
18 juil. 2017 16h01 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., July 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an...
Inovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
06 juil. 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive...
Inovio Announces Leadership Appointments
28 juin 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and...
Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
19 juin 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled...
Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
15 juin 2017 08h00 HE
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico...